Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PROGRESS: PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery

NCT02804776 is registered in ClinicalTrials.gov with National Cancer Centre, Singapore as lead sponsor.

NCT NCT02804776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02804776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PROGRESS: PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery
Lead sponsor
National Cancer Centre, Singapore
Phase
Phase 2
Overall status
Completed
Start date
January 27, 2015
Completion date
February 21, 2018
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer